for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Biogen Inc

BIIB.O

Latest Trade

295.55USD

Change

-4.71(-1.57%)

Volume

2,067,944

Today's Range

295.46

 - 

304.32

52 Week Range

215.78

 - 

344.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
300.26
Open
300.27
Volume
2,067,944
3M AVG Volume
48.62
Today's High
304.32
Today's Low
295.46
52 Week High
344.00
52 Week Low
215.78
Shares Out (MIL)
184.45
Market Cap (MIL)
54,179.48
Forward P/E
9.08
Dividend (Yield %)
--

Next Event

Q4 2019 Biogen Inc Earnings Release

Latest Developments

More

Biogen Announces Positive Phase 2 Study Results For Cutaneous Lupus Erythematosus And Systemic Lupus Erythematosus

FDA Accepts Samsung Bioepis’ BLA For SB8 Bevacizumab Biosimilar Candidate

Alkermes: Receipt Of $150 Mln Milestone Payment From Biogen Related To FDA Approval Of Vumerity

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Biogen Inc

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.

Industry

Biotechnology & Drugs

Contact Info

225 Binney St

+1.781.4642000

https://www.biogen.com/

Executive Leadership

Stelios B. Papadopoulos

Independent Chairman of the Board

Michel Vounatsos

Chief Executive Officer, Director

Jeffrey D. Capello

Chief Financial Officer, Executive Vice President

Ginger Gregory

Chief Human Resource Officer, Executive Vice President

Susan H. Alexander

Executive Vice President, Chief Legal Officer and Secretary

Key Stats

2.75 mean rating - 32 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

11.4K

2017

12.3K

2018

13.5K

2019(E)

14.2K
EPS (USD)

2016

20.220

2017

21.810

2018

26.200

2019(E)

33.067
Price To Earnings (TTM)
10.63
Price To Sales (TTM)
3.81
Price To Book (MRQ)
3.90
Price To Cash Flow (TTM)
9.05
Total Debt To Equity (MRQ)
42.54
LT Debt To Equity (MRQ)
31.85
Return on Investment (TTM)
24.17
Return on Equity (TTM)
20.70

Latest News

Latest News

Biogen builds case for its Alzheimer's drug, skeptics say more data needed

Biogen Inc on Thursday laid out more data on its experimental Alzheimer's drug that raised no major safety alarms but also offered little compelling evidence the drug, once declared a failure, actually works.

UPDATE 3-New Biogen data showed no major safety issues for its Alzheimer's drug

Biogen Inc on Thursday presented new data on its experimental Alzheimer's drug aducanumab that eased concerns raised by some experts but still left many questions unanswered as the company made its case about why it plans to seek U.S. approval after declaring the drug a...

Biogen presents new data on its controversial Alzheimer's drug

Biogen Inc on Thursday presented new data from on its experimental Alzheimer's drug aducanumab showing that no patients in a high-risk group that were genetically predisposed to get Alzheimer's died while taking the high dose of the drug, which had been a key concern.

Novartis R&D boss says doesn't see big opportunity in oral SMA therapy

Novartis research head Jay Bradner said on Thursday the Swiss drugmaker is focusing efforts against spinal muscular atrophy (SMA) on gene therapy Zolgensma and retreating from oral therapy like its molecule LMI070, also called branaplam.

Biogen to make case to skeptics for its controversial Alzheimer's drug

Biogen Inc, looking to win over skeptics and health regulators, later on Thursday will present highly anticipated data on its experimental Alzheimer's drug aducanumab, which the U.S. biotech company had declared a failure earlier this year.

Roche eyes quick FDA approval in SMA race with Biogen, Novartis

Roche expects its risdiplam medicine for spinal muscular atrophy to get U.S. approval by next May, the Swiss drugmaker said on Monday, as it takes on Novartis and Biogen in the lucrative rare disease area.

Roche drug for spinal muscular atrophy hits target in late-stage trial

Roche's bid to rival Biogen and Novartis in treating spinal muscular atrophy (SMA) got a lift on Monday when the Swiss drugmaker said its drug risdiplam improved motor function in a key study.

Roche sets sights on Novartis, Biogen as SMA trial hits target

Roche's bid to rival Biogen and Novartis in treating spinal muscular atrophy (SMA) got a lift on Monday when the Swiss drugmaker said its drug risdiplam improved motor function of patients in a key study.

Small relief for Biogen in MS drug approval

The U.S. Food and Drug Administration on Wednesday approved Biogen Inc's new oral drug to treat multiple sclerosis, offering the drugmaker some relief as its core franchise faces patent challenges.

FDA approves multiple sclerosis drug from Biogen and Alkermes

Biogen Inc and partner Alkermes Plc said on Wednesday that the U.S. Food and Drug Administration approved their oral drug to treat multiple sclerosis.

Biogen, Eisai revive plans for Alzheimer's drug, surprising market

Biogen Inc <BIIB.O> revived plans on Tuesday to seek U.S. approval for Alzheimer's treatment aducanumab, surprising investors and saying data from more patients in two discontinued studies showed the drug reduced the decline of patients.

US STOCKS SNAPSHOT-Wall St opens higher on upbeat earnings, healthcare boost

Wall Street opened higher on Tuesday after a batch of upbeat earnings reports eased concerns over domestic growth and the fallout from the U.S.-China trade war, while a surge in Biogen boosted the healthcare sector.

Biogen third-quarter profit rises 7% on Spinraza strength

Drugmaker Biogen Inc <BIIB.O> reported a 7.1% rise in third-quarter profit on Tuesday, boosted by higher demand for its rare muscle disease drug, Spinraza.

Biogen to seek U.S. approval for Alzheimer's drug; shares jump 16%

Drugmaker Biogen Inc said on Tuesday it was planning to file for U.S. regulatory approval for its Alzheimer's treatment aducanumab after fresh analysis of its clinical trial showed promise.

Biogen scraps two late-stage trials for Alzheimer's treatment

Biogen Inc and Eisai Co Ltd are abandoning two late-stage trials for their Alzheimer's treatment in a widely anticipated move that comes months after the companies scrapped trials of another drug for the memory-robbing disease.

Biogen scraps two late-stage Alzheimer's trials

Biogen Inc and partner Eisai Co Ltd said on Friday they would abandon two late-stage trials testing their experimental treatment, elenbecestat, for patients with early Alzheimer's disease.

Multiple sclerosis drug helps Biogen beat Wall Street profit expectations

Biogen Inc <BIIB.O> reported better-than-expected second quarter profit and raised its 2019 earnings forecast on Tuesday, driven by higher sales of its top-selling multiple sclerosis drug Tecfidera and lower taxes.

Biogen profit rises 72%

Drugmaker Biogen Inc reported a 72.4% rise in second-quarter profit on Tuesday, boosted by higher sales of its multiple sclerosis treatment Tecfidera and lower research and development costs.

NHS England, Biogen reach deal on pricey drug for deadly disorder

England's National Health Service said it had reached a deal to pay for U.S. drugmaker Biogen Inc's expensive spinal muscle atrophy treatment Spinraza.

NHS England, Biogen reach deal on pricey drug for deadly disorder

England's National Health Service said it had reached a deal to pay for U.S. drugmaker Biogen Inc's expensive spinal muscle atrophy treatment Spinraza.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up